Curated News: National Institute of Allergy and Infectious Diseases (NIAID)

• share
• favorite_border

People who are just beginning treatment for high blood pressure can benefit equally from two different classes of medicine - angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) - yet ARBs may be less likely to cause medication side effects, according to an analysis of real-world data published today in Hypertension, an American Heart Association journal.

• share
• favorite_border

In what turned out to be one of the most important accidents of all time, Scottish bacteriologist Alexander Fleming returned to his laboratory after a vacation in 1928 to find a clear zone surrounding a piece of mold that had infiltrated a petri dish full of Staphylococcus aureus (S. aureus), a common skin bacterium he was growing.

• share
• favorite_border

UNC-Chapel Hill scientists investigated blood samples from children enrolled in a dengue vaccine trial to identify the specific kinds of antibody responses that correlate with protection against dengue virus disease.

• share
• favorite_border

Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus. Olena Shtanko, Ph.D., a Staff Scientist at the Texas Biomedical Research Institute (Texas Biomed), has received more than $1 million from the National Institutes of Health (NIH) to explore different aspects of Ebola virus infection.

• share
• favorite_border

What exactly triggers a sneeze? A team led by researchers at Washington University School of Medicine in St. Louis has identified, in mice, specific cells and proteins that control the sneeze reflex. Better understanding of what causes us to sneeze — specifically how neurons behave in response to allergens and viruses — may point to treatments capable of slowing the spread of infectious respiratory diseases.

• share
• favorite_border

In a study published today in the Annals of Internal Medicine, Johns Hopkins Medicine researchers say they believe that, for the first time, there is evidence to show that three doses of vaccine increase antibody levels against SARS-CoV-2 — the virus that causes COVID 19 — more than the standard two-dose regimen for people who have received solid organ transplants.

• share
• favorite_border

Researchers at Penn State College of Medicine are participating in a national clinical trial evaluating whether people who have previously experienced severe allergic reactions are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.

• share
• favorite_border

The La Jolla Institute for Immunology (LJI) is partnering with Synbal, Inc., a preclinical biotechnology company based in San Diego, CA, to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI will be led by Professor Sujan Shresta, Ph.D., a member of the Institute’s Center for Infectious Disease and Vaccine Research.

• share
• favorite_border

Researchers at Washington University School of Medicine in St. Louis have found that although the vast majority of people with alcohol use disorder see their doctors regularly for a range of issues, fewer than one in 10 ever get treatment to help curb their drinking.

• share
• favorite_border

A new University of California, Irvine-led study finds low serum levels of the sugar N-acetylglucosamine (GlcNAc), is associated with progressive disability and neurodegeneration in multiple sclerosis (MS).

• share
• favorite_border

Rajesh Kumar, MD, and Jacqueline Pongracic, MD, from Ann & Robert H. Lurie Children’s Hospital of Chicago received $3 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) for a site-specific clinical trial on whether a soy supplement in infancy can prevent asthma in children with a high-risk genetic variation. This will be one of the earliest precision medicine approaches to asthma prevention.

• share
• favorite_border

The lab of Rahima Benhabbour, PhD, has received a $3.74 million grant over five years from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant will fund the creation of an injectable that will provide long-acting protection for women against sexually transmitted pathogens and prevent pregnancy, but is also removable.

• share
• favorite_border

Penn Medicine has been selected as one of five sites across the country to serve as a Center of Excellence for Influenza Research and Response (CEIRR), with the goal of better understanding influenza viruses around the world along with learning about the viral strains that have the potential to cause pandemics. Penn Medicine has been awarded nearly $7 million in first-year funding.

• share
• favorite_border

Clusters of a virus known to cause stomach flu are resistant to detergent and ultraviolet disinfection, according to new research co-led by Danmeng Shuai, Ph.D., an associate professor of civil and environmental engineering at the George Washington University and Nihal Altan-Bonnet, Ph.D., a senior investigator and the head of the Laboratory of Host-Pathogen Dynamics at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

• share
• favorite_border

Scientists at Washington University School of Medicine in St. Louis have implicated a type of immune cell in the development of chronic lung disease that sometimes is triggered following a respiratory viral infection. The evidence suggests that activation of this immune cell serves as an early switch that, when activated, drives progressive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).

• share
• favorite_border

DNA sequencing of bacteria found in pigs and humans in rural eastern North Carolina, an area with concentrated industrial-scale pig-farming, suggests that multidrug-resistant Staphylococcus aureus strains are spreading between pigs, farmworkers, their families and community residents, and represents an emerging public health threat, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

• share
• favorite_border

Houston Methodist has sequenced more than 20,000 of Houston’s coronavirus genomes since the start of the pandemic and leads the SARS-CoV-2 genome sequencing efforts in the U.S. In the most recent batches of genomes, the U.K., South Africa, Brazil, California and New York variants were detected.

• share
• favorite_border

Researchers at Henry Ford Health System, as part of a national asthma collaborative, have identified a gene variant associated with childhood asthma that underscores the importance of including diverse patient populations in research studies. The study is published in the print version of the American Journal of Respiratory and Critical Care Medicine.

• share
• favorite_border

Using venom from the Conus nux, a sea snail, a first-of-its-kind study suggests these conotoxins could potentially treat malaria. The study provides important leads toward the development of new and cost-effective anti-adhesion or blockade-therapy drugs aimed at counteracting the pathology of severe malaria. Similarly, mitigation of emerging diseases like COVID-19 also could benefit from conotoxins as potential inhibitors of protein-protein interactions as treatment. Venom peptides from cone snails has the potential to treat myriad diseases using blockage therapies.

• share
• favorite_border

The study also showed that the number of COVID-19 infections in pregnant patients from nearly all communities of color in Washington was high. There was a twofold to fourfold higher prevalence of pregnant patients with COVID-19 infections from communities of color than expected based on the race-ethnicity distribution of pregnant women in Washington in 2018.

• share
• favorite_border

The AIDS Clinical Trials Group has added rapid infusion, intramuscular injection, an inhalant, and an oral agent to its ACTIV-2 phase 2 and 3 evaluations of multiple investigational agents for treating early, symptomatic COVID-19 in a single trial for outpatient treatment.

• share
• favorite_border

The finding could lead to new ways to prevent cold sores and herpes-related eye disease from reoccurring, the researchers report.

• share
• favorite_border

A vaccine for use against the deadly Nipah and Hendra viruses has demonstrated effectiveness in preclinical studies as early as 7 days following a single immunization, according to a new study, "A Single Dose Investigational Subunit Vaccine for Human Use against Nipah virus and Hendra virus," published in the journal, npj Vaccines, online February 8, 2021.

• share
• favorite_border

GRAND RAPIDS, Mich. (Feb. 3, 2021) — A pair of scientists from Van Andel Institute and the National Institute of Allergy and Infectious Diseases have been granted a three-year, $1.5 million Allen Distinguished Investigator award from The Paul G. Allen Frontiers Group, a division of the Allen Institute, to better understand how diet and metabolism influence the immune system’s ability to fight off threats such as infections.

• share
• favorite_border

A $1.2. million challenge grant from the Mabee Foundation brings Texas Biomedical Research Institute (Texas Biomed) closer to its goal of $10 million to fund the construction of its Nonhuman Primate Animal Facility (NHP ALFA) on its campus. The Institute is more than halfway to its goal. This project will accommodate the critical need of the Southwest National Primate Research Center (SNPRC) to provide innovative, contemporary accommodations and laboratory space for animals involved in research that aid in testing the safety and efficacy of new and improved diagnostics, therapies and vaccines at a larger scale.

• share
• favorite_border

The study, which followed 240 pregnant women between March and June 2020, found that the COVID-19 mortality rate in the pregnant women was significantly higher when compared to the COVID-19 mortality rate in similarly aged individuals within Washington state.

• share
• favorite_border

The University of Miami Health System is one of five sites nationally and the only one in the Southeast U.S. chosen to participate in a National Institute of Allergy and Infectious Diseases (NIAID) study looking at people who have had COVID-19 or have had a COVID-19 vaccine to examine the durability and robustness of participants’ antibody and T-cell responses to the virus.

• share
• favorite_border

Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases has received the 2020 American Society for Cell Biology Public Service Award.

• share
• favorite_border

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, has been re-funded for the next seven years by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and collaborating NIH Institutes.

• share
• favorite_border

Anthony S. Fauci, MD, will discuss COVID-19 – including the latest on potential vaccines – in a free Zoom presentation at noon Nov. 18 during Medical Center Hour at the University of Virginia School of Medicine.

• share
• favorite_border

Keck Medicine of USC is enrolling individuals in a phase 3 clinical trial to test monoclonal antibody treatment for COVID-19

• share
• favorite_border

A new saliva-based test developed by a team at Johns Hopkins Bloomberg School of Public Health has been found to accurately detect the presence of antibodies to SARS-CoV-2, the virus that causes COVID-19.

• share
• favorite_border

Newborns and young infants are particularly susceptible to the flu and are six times more likely to die from the infection than older children. Currently there is no flu vaccine available for babies less than 6 months old.

• share
• favorite_border

Artificial light abnormally increases mosquito biting behavior at night in a species that typically prefers to bite people during the day, according to research from the University of Notre Dame that was published in The American Journal of Tropical Medicine and Hygiene.

• share
• favorite_border

At night in a Ugandan forest, a team of American and African scientists take oral swabs from insect-eating cyclops leaf-nosed bats. In a necropsy room near the Baltic Sea, researchers try to determine what killed a donkey, a Bennett’s tree-kangaroo and a capybara at a German zoo — all of them suffering from severe brain swelling. Neither team was aware of the other, yet they were both about to converge on a discovery that would forever link them — and help solve a long-enduring mystery.

• share
• favorite_border

In a new study, infectious disease researchers show that HIV viremia isn’t always nonadherence to medication or resistance to the drugs. Instead, the patients are victims of what the scientists have dubbed “repliclones” – large clones of HIV-infected cells that produce infectious virus particles.

• share
• favorite_border

In a new study, researchers at La Jolla Institute for Immunology (LJI) report that a protein called TL1A drives fibrosis in several mouse models, triggering tissue remodeling, and making it harder for lungs and airways to function normally.

• share
• favorite_border

In a new Immunity study, researchers at La Jolla Institute for Immunology (LJI) show that one way to improve the body's immune response to vaccines is to factor in antigen valency. Valency refers to the number of antibody binding sites on an antigen.

• share
• favorite_border

Scientists have developed an injectable drug that blocks HIV from entering cells. They say the new drug potentially offers long-lasting protection from the infection with fewer side effects.

• share
• favorite_border

Scientists at Johns Hopkins Medicine, experimenting with a small number of human cell samples, report that the “hook” of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining cells of the rest of the nose and windpipe that leads to the lungs. These supporting cells are necessary for the function/development of odor-sensing cells. The findings, from a preliminary study of cells lining both the nose and trachea, could advance the search for the best target for topical or local antiviral drugs to treat COVID-19, and offers further clues into why people with the virus sometimes lose their sense of smell.

• share
• favorite_border

Mayo Clinic and collaborators have published a preprint that identifies two main signals of efficacy that can inform future clinical trials on plasma therapy on COVID-19 patients. The data are extracted from the Mayo-led national Expanded Access Program (EAP) for convalescent plasma for the treatment of hospitalized patients with COVID-19.

• share
• favorite_border

The National Institutes of Health will soon launch a phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.

• share
• favorite_border

Findings from a research study, led by scientists at Henry Ford, suggest an enzyme could play an important role in the treatment of cancer and autoimmune diseases in the airway.

• share
• favorite_border

Children in low-income neighborhoods in Baltimore tended to have more asthma symptoms when levels of the synthetic chemical BPA (Bisphenol A) in their urine were elevated, according to a study from researchers at the Johns Hopkins Bloomberg School of Public Health and School of Medicine.

• share
• favorite_border

The George Washington University will participate in a clinical trial for an investigational COVID-19 vaccine.

• share
• favorite_border

Widespread use of pesticides and other agrochemicals can speed the transmission of the debilitating disease schistosomiasis, while also upsetting the ecological balances in aquatic environments that prevent infections, finds a new study led by researchers at the University of California, Berkeley.

• share
• favorite_border

While 93 percent of U.S. pediatricians surveyed were aware of the national guidelines on peanut allergy prevention in infants, only 30 percent were fully implementing the recommended practices and 64 percent reported partial implementation, according to the study published in JAMA Network Open.